Evaluation of maternal morbidity after drug-induced termination of pregnancy (TOP) after 12 gestation weeks;Évaluation de la morbidité maternelle après interruption médicamenteuse de grossesse à partir de 12 semaines d'aménorrhée

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 32, Issue 3 I, 2003, Pages 227-238

  Guillem, P ^a   Racinet, C ^a   Leynaud, A ^b   Benbassa, A ^c   Cans, C ^b  

^a RHEOP   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c Clinique Belledonne   (France)

Author keywords

Infection; Pregnancy termination; Retention; Transfusion; Uterine rupture

Indexed keywords

ARTICLE; AUSTRALIA; BLOOD TRANSFUSION; CALCULATION; CANADA; CLINICAL TRIAL; DISEASE SEVERITY; EUROPEAN UNION; EVALUATION; GESTATIONAL AGE; HUMAN; HYSTERECTOMY; INFECTION RATE; INFECTION RISK; MATERNAL MORBIDITY; MATERNAL MORTALITY; MEDLINE; META ANALYSIS; METRITIS; NEW ZEALAND; OUTCOMES RESEARCH; PREGNANCY TERMINATION; RETAINED PLACENTA; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; STATISTICAL ANALYSIS; TECHNIQUE; THERAPEUTIC ABORTION; THIRD TRIMESTER PREGNANCY; TREATMENT INDICATION; UNITED STATES; UTERUS BLEEDING; UTERUS RUPTURE; FEMALE; INDUCED ABORTION; INFECTION; METHODOLOGY; PREGNANCY; STATISTICS;

ABORTIVE AGENT;

ABORTIFACIENT AGENTS; ABORTION, INDUCED; BLOOD TRANSFUSION; FEMALE; GESTATIONAL AGE; HUMANS; INFECTION; MATERNAL MORTALITY; PLACENTA, RETAINED; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; UTERINE RUPTURE;

EID: 0042266740     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Faraut T, Cans C, Althuser M, Jouk PS. Utilisation conjointe 3de la clarté nucale, de l'âge gestationnel et de l'âge maternel pour l'estimation du risque de trisomie 21. J Gynecol Obstet Biol Reprod 1999; 28: 439-45.
2. Stoll C, Alembik Y, Dott B, Roth MP, Finck S. Evaluation of prenatal diagnosis by a registry of congenital anomalies. Prenat Diagn 1992; 12: 263-270.
3. Registre des Handicaps de l'Enfant et Observatoire Périnatal. Interruption volontaire de grossesse pour motif thérapeutique. Rapport annuel, 1998, RHEOP, Grenoble-France.
4. Couzinet B, Le Strat N, Ulmann A, Baulieu EE, schaison G. Termination of early pregnancy by the progesterone antagonist RU 486 (mifepristone). N Eng J Med 1986; 315: 1565-70.
5. Hill NC, Selinger M, Ferguson J, Lopez Bernal A, Mackenzie IZ. The physiological and clinical effects of progesterone inhibition with mifepristone (RU486) in the second trimester. Br J Obstet Gynecol 1990; 97: 487-92.
6. Maria B, Matheron I. Les méthodes d'interruption de grossesse du deuxième trimestre et d' évacuation des morts fœtales in utero. J Gynecol Obstet Biol Reprod 1994; 23: 642-50.
7. Pons JC, Rais S, Diochin P, Frydman R. RU 486 (mifépristone) et interruption volontaire de grossesse pour motif thérapeutique au deuxième et au troisième trimestre. J Gynecol Obstet Biol Reprod 1992; 21: 255-7.
8. Chapman SJ, Crispens M, Owen J, Savage K. Complications of midtrimester pregnancy termination: the effect prior cesarean delivery. Am J Obstet Gynecol 1996; 176: 889-92.
9. Fliers E, Duren DR, Van Zwieten PA. A prostaglandin analogue as a probable cause of myocardial infarction in a young woman. BMJ 1991; 302: 416.
10. Jannet D, Aflak N, Chemla JP, Marpeau L, Milliez J. Mifépristone et misoprostol dans les interruptions médicales de grossesses. J Gynecol Obstet Biol Reprod 1996; 25: 277-82.
11. Larue L, Marpeau L, Percque M, Castiel J, Guettier X, Maghioracos P, et al. Rupture d'un utérus sain lors d' une interruption de grossesse par prostaglandines au deuxième trimestre. J Gynecol Obstet Biol Reprod 1991; 20: 269-72.
12. Nuutila M, Toivonen J, Ylikorkala O, Halmesmaki E. A comparison between two doses of intra vaginal misoprostol and gemeprost for induction of second-trimester abortion. Obstet Gynecol 1997; 90: 896-900.
13. Owen J, Hauth JC. Concentrated oxytocin plus low-dose prostaglandin e2 compared with prostaglandin e2 vaginal suppositories for second-trimester pregnancy termination. Obstet Gynecol 1996; 88: 110-13.
14. Peat B. second trimester abortion by extra-amniotic PGF2α infusion: experience of 178 cases. Aust N Z Obstet Gynecol 1991; 31: 47-51.
15. Zimbris L, Boulot P, Giacalone PL, Hoffet M, Sarda P, Molenat F, et al. Prise en charge des interruptions médicales de grossesse de 1986 à 1994. J Gynecol Obstet Biol Reprod 1997; 26: 76-84.
16. Ferguson JE, Burkett BJ, Pinkerton JV, Thiagarajah S, Flather MM, Martel MM, et al. Intraamniotic 15(s)-15-methyl-prostaglandin F2α and termination of middle and late second trimester pregnancy for genetic indications: a contemporary approach. Am J Obstet Gynecol 1993; 169: 332-40.
17. Hern MW. Laminaria versus Dilapan osmotique cervical dilatators for outpatient dilatation and evacuation abortion: randomized cohort comparison of 1001 patients. Am J Obstet Gynecol 1994; 171: 1324-8.
18. Schulman LP, Ling FW, Meyers CM, Shanklin DR, Simpson JL, Elias S. Dilatation and evacuation for second-trimester genetic pregnancy termination. Obstet Gynecol 1990; 75: 1037-40.
19. Thomas AG, Alvarez M, Friedman F, Brodman ML, Kim J, Lockwood C. The effect of placenta on blood loss in second-trimester pregnancy termination. Obstet Gynecol 1994; 84: 58-60.
20. Berger D, Odent S, Leveque J, Milon J, Grall JY, Poulain P. Interruption thérapeutique de grossesse. Diagnostics et protocoles à propos de 54 cas. Rev Fr Gynecol Obstet 1991; 86: 498-502.
21. Dommergues M, Benachi A, Benifla JL, Des Noettes R, Dumez Y. The reasons for termination of pregnancy in the third trimester. Br J Obstet Gynecol 1999; 106: 297-303.
22. Hill NCW, Mackenzie IZ. Second trimester terminations using extra amniotic or intra amniotic prostaglandin E2: an analysis of efficacy and complications. Br J Obstet Gynecol 1989; 96: 1424-31.
23. rd trimesters of pregnancy using a synthetic of prostaglandin E2, sulprostone, administrated intravenously. Based upon 182 cases. Eur J Obstet Gynecol Reprod Biol 1993; 50: 99-104.
24. Persch M, Abrar D, Leonard J, Bonhomme JP, Simon E, Gillet JY. Interruption médicale de grossesse. Indications et techniques. Etude critique et réflexions à propos de 324 cas. Rev Fr Gynecol Obstet 1992; 87: 70-5.
25. Urquhart DR, Bahzad C, Templeton AA. Efficacy of the antiprogestin mifepristone (RU486) prior to prostaglandin termination of pregnancy. Hum Reprod 1989; 4: 202-3.
26. Wadhera S, Millar WJ. Second trimester abortions: trends and medical complications. Health Reports 1994; 6: 441-454.
27. Allen J, Uldbjerg N, Petersen LK, Secher NJ. Intracervical 17-oestradiol before induction of second trimester abortion with prostaglandine. Eur J Obstet Gynecol Reprod Biol 1989; 33: 123-7.
28. D'Ercole C, Blanc B, Boubli L, Bautrant E, Nadal F, Eyraud B. Effets d'une préinduction par la mifépristone sur les interruptions mėdicales des deuxième et troisième trimestres de grossesse réalisées par sulprostone par voie intraveineuse. Rev Fr Gynecol Obstet 1992; 87: 277-80.
29. El Refaey H, Hinshow K, Templeton A. The arborifacient effect of misoprostol in the second trimester. A randomised comparison with gemeprost in patients pre-treated with mifepristone (RU486). Hum Reprod 1993; 8: 1744-6.
30. El Refaey H, Templeton A. Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: a randomised comparison between two misoprostol regimens. Hum Reprod 1995; 10: 475-8.
31. Rodger MW, Baird TD. Pretreatment with mifepristone (RU486) reduces interval between prostaglandin administration and expulsion in second trimester abortion. Br J Obstet Gynecol 1990; 97: 41-5.
32. Thong KJ, Baird DT. A study of gemeprost alone, dilapan or mifepristone in combination with gemeprost for the termination of second trimester pregnancy. Contraception 1992; 46: 11-7.
33. Thong KJ, Lynch P, Baird DT. A randomised study of two dose of gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. Contraception 1996; 54: 97-100.
34. Urquhart DR, Templeton AA. The use of mifepristone prior to prostaglandin-induced mid-trimester abortion. Hum Reprod 1990; 5: 883-6.
35. Webster D, Penney GC, Templeton AA. A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol. Br J Obstet Gynecol 1996; 103: 706-9.
36. Zamblera D, Thilaganathan B, Parsons J. Randomised trial of hypan versus gemeprost in cervical preparation prior to second termination of pregnancy. Br J Obstet Gynecol 1994; 101: 543-4.
37. e trimestres. J Gynecol Obstet Biol Reprod 1998; 27: 83-6.
38. Maria B, Soudre G, Stampf F. Utilisation de la mifépristone en prétraitement de l'interruption de grossesse du 2e trimestre. Press Med 1989; 18: 1933.
39. Querido L, Haspels AA. Late second trimester abortion with 16, 16-dimethyl-trans-α2-PGE1 methyl ester (gemeprost). Contraception 1990; 42: 43-9.
40. Thong KJ, Baird DT. Induction of second Trimester abortion with mifepristone and gemeprost. Br J Obstet Gynecol 1993; 100: 758-61.
41. UK Multicenter Group. Oral mifepristone 600 mg and vaginal gemeprost for mid-trimester induction of abortion. Contraception 1997; 56: 361-6.
42. e trimestres. J Gynecol Obstet Biol Reprod 1994; 23: 701-5.
43. Boulot P, Hoffet M, Bachelard B, Lefort G, Hedon B, Laffargue F, et al. Late vaginal induced abortion after a previous cesarean birth: potential for uterine rupture. Gynecol Obstet Invest 1993; 36: 87-90.
44. Bowers CH, Chervenak JL, Chervenak FA. Late second trimester pregnancy termination with dilatation and evacuation in critically ill women. J Reprod Med 1989; 34: 880-3.
45. Byrne P, Onyekwuluje T. Uterine rupture after termination of pregnancy with gemeprost. BMJ 1991; 30: 852.
46. Darney PD, Atkinson E, Hirabayaski K. Uterine Perforation During Second-Trimester Abortion by Cervical Dilatation and Instrumental Extraction. Obstet Gynecol 1990; 75: 441-3.
47. Kalra PA, Litherland D, Sallomi DF, Critchley HOD, Falconer GF, et al. Cardiac standstill induced by prostaglandin pessaries. Lancet 1989; 24: 1460-1.
48. Levy DM, Hinshaw K, Knox FM, Campbell DM, Sutherland HW. Cardiogenic pulmonary oedema: presentation of preeclampsia exacerbated by prostaglandin arbortifacients. Br J Obstet Gynecol 1994; 101: 263-5.
49. rd trimesters of pregnancy. Eur J Obstet Gynecol Reprod Biol 1993; 50: 105-8.
50. Norman JE. Uterine rupture during therapeutic abortion in the second trimester using mifepristone and prostaglandin. Br J Obstet Gynecol 1995; 10: 332-3.
51. Phillips K, Berry C, Mathers AM. Uterine rupture during second trimester termination of pregnancy using mifepristone and a prostaglandin. Eur J Obstet Gynecol Reprod Biol 1996; 65: 175-6.
52. Thong KJ, Lynch P, Baird DT. Uterine rupture during therapeutic abortion in the second trimester using mifepristone and prostaglandin. Br J Obstet Gynecol 1995; 10: 844-5.
53. Vine SJ, Prys-Davies A, Pearson JF. Transverse posterior cervicoisthmic rupture after gemeprost pessaries for termination. BMJ 1992; 305: 1332.
54. Wasson AW, Stubblefield PG. Use of coagulation analyser in mananaging disseminated intravascular coagulation after midtrimester pregnancy termination. J Report Med 1994; 39: 835-7.
55. Wein P, Robertson B, Ratten GJ. Cardiorespiratory collapse and pulmonary oedema due to intravascular abortion of Prostaglandin F2α administrated extraamniotically for midtrimester of pregnancy. Aust N Z Obstet Gynaecol 1989; 29: 261-3.
56. Wierner JJ, Evans AS. Uterine rupture in midtrimester abortion. A complication of gemeprost vaginal pessaries and oxytocin. Case report. Br J Obstet Gynecol 1990; 97: 1061-2.
57. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomised clinical trials. Stat Med 1991; 10: 1665-77.
58. Body G, Soutoul JH. Interruption médicale de grossesse aux deuxième et troisième trimestres. Aspects techniques indications et responsabilités médicales, problèmes éthiques et juridiques. EMC Obstet 1994, 5-032-A-50, 1-8.
59. Malmstrom H, Hemmingsson E. Uterine rupture as a complication of second-trimester abortion when using prostaglandin F2 alpha together with other oxytocic agents. Acta Obstet Gynecol Scand, 1984; 63: 271-2.
60. Kone M, Diarra S. La rupture utérine. EMC Obstet, 1995, 5-080-A-10, 2.